Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 14/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24663745 | 0.83 | GRM1 (0.40) | GRM1OPRM1EPHX2ADORA3 | |
| SCHEMBL1132078 | 0.82 | — | — | |
| SCHEMBL8784882 | 0.78 | ADORA3 (0.37) | GRM1OPRM1EPHX2HTR1ADRD2 | |
| SCHEMBL12986792 | 0.76 | MAPT (0.41) | — | |
| SCHEMBL2990561 | 0.76 | EPHX2 (0.39) | GRM1OPRM1EPHX2ADORA3MAPK8 | |
| SCHEMBL4433068 | 0.76 | ALDH1A1 (0.47) | — | |
| SCHEMBL17803022 | 0.76 | EPHX2 (0.39) | GRM1OPRM1EPHX2ADORA3MAPK8 | |
| SCHEMBL28034927 | 0.75 | CHRNB2 (0.38) | GRM1EPHX2ADORA3MAPK8MAPK10 | |
| SCHEMBL28003109 | 0.75 | CHRNB2 (0.38) | GRM1EPHX2ADORA3MAPK8MAPK10 | |
| SCHEMBL28034929 | 0.75 | CHRNB2 (0.38) | GRM1EPHX2ADORA3MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | GRM1 2644/4885OPRM1 4069/4885EPHX2 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.